Orexo AB (0H19) AI Stock Analysis

0 Followers

Orexo AB

(LSE:0H19)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Partner-funded platform strategyA partner-funded development model can preserve access to multiple growth opportunities while limiting Orexo’s direct cash exposure. If collaborations mature into milestones, royalties, or commercial launches, the strategy could improve capital efficiency and diversify future revenue beyond legacy products.

Negative Factors

Severe revenue contractionThe sharp contraction indicates that Orexo currently has a much smaller operating base than in prior periods, while fixed and development costs remain substantial. Persistently low revenue can weaken commercial leverage, make recovery dependent on pipeline execution, and prolong losses even if gross margins remain high.

Orexo AB (0H19) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 5.66M
Dividend Yield: ―
Average Volume (3M): 16.14K
Price to Earnings (P/E): -0.1
Beta (1Y): -0.22
Revenue Growth: -97.68%
EPS Growth: -83.26%
Country: UK
Employees: 61
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Orexo AB Business Overview & Revenue Model

Company Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatme...

Orexo AB Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:-73.08%|Next Earnings Date:Feb 04, 2027

Earnings Call SentimentPositive

The call had a cautiously positive operational tone, with meaningful progress on Izipry, OX640, OX390, semaglutide, partnerships, and cost restructuring. However, the company continues to face substantial financial pressures, including low revenue, a SEK 118 million loss from continued operations, negative cash flow, reduced own cash of SEK 62 million, large historical Zubsolv-related obligations, and pending regulatory and partnering milestones. The number and importance of development milestones and the planned rights issue outweighed the challenges, supporting an overall positive sentiment.

Positive Updates

Progress in Strategic Transformation

Orexo said it made substantial progress toward becoming a platform-focused company, including restructuring its balance sheet and operations, streamlining costs, and focusing on partnerships around the AmorphOX platform.

Negative Updates

Low Quarterly Revenue

Revenue from continued operations was SEK 0.8 million in Q3. Abstral royalties were low because individual country royalty agreements continue to expire, while Edluar royalties declined following generic product launches in Canada.

Company Guidance

Orexo expects Izipry to have a six months of review time, with approval expected in the end of Q1 next year; OX640 is on track to start its pivotal trial in Q4, with results expected in first half of next year, potentially into the beginning of Q2, and the company expects to announce the trial start also in this quarter. Normalized OpEx was SEK 55 million or SEK 18 million per month, but the 18 is higher than where they are aiming, and OpEx is expected to further decline in 2027, with cash flow getting closer to the EBITDA; the ambition is to have a runway taking the company past 2027 without income from partnering. The Zubsolv earn-out is expected in Q1 of next year, BARDA resource contribution is up to $54 million, and the DOJ payment is provisioned at up to $4 million over several years, while no significant numbers are foreseen from Zubsolv rebates moving from now on.

Orexo AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0H19 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	78Outperform	SEK 44.63B	58.19	16.50%	―	2.96%	-4.07%
SE:SOBI	72Outperform	SEK 167.58B	25.46	15.99%	―	14.79%	26766.85%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZCUR	49Neutral	SEK 921.15M	43.67	65.99%	―	―	―
SE:XSPRAY	43Neutral	SEK 598.24M	-3.28	-25.14%	―	―	44.46%
SE:IRLAB.A	42Neutral	SEK 317.50M	-0.95	-97.06%	―	4.74%	66.33%

* Healthcare Sector Average

Performance Comparison

GB:0H19 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0H19	Orexo AB	1.03	-16.54	-94.13%
SE:SOBI	Swedish Orphan Biovitrum Ab	487.00	146.80	43.15%
SE:CAMX	Camurus AB	739.00	95.50	14.84%
SE:ALZCUR	AlzeCure Pharma AB	6.52	4.76	270.45%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	0.62	-1.65	-72.69%
SE:XSPRAY	Xspray Pharma AB	11.28	-13.18	-53.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Orexo AB AI Stock Analysis